Company
Headquarters: Guangzhou, China
Employees: 32,337
CN¥20.23 Billion
CNY as of Jan. 1, 2026
US$2.88 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. The company was founded in 1999 and is based in Guangzhou, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥26.83 B |
| EBITDA | CN¥1.67 B |
| Gross Profit TTM | CN¥9.22 B |
| Profit Margin | 4.24% |
| Operating Margin | 7.01% |
| Quarterly Revenue Growth | 2.50% |
DaShenLin Pharmaceutical Group Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603233 wb_incandescent